Onesource Specialty Pharma

Onesource Specialty Pharma EBIT Growth

The Year-over-Year EBIT Growth of Onesource Specialty Pharma (ONESOURCE.NS) as of Oct 22, 2026 is -86.80 %.

EBIT Growth

-86.80 %

Last updated:

Year-over-Year EBIT Growth of Onesource Specialty Pharma is 2026 -86.80 % . Year-over-Year EBIT Growth of Onesource Specialty Pharma was 2025 - . It decreases by % lower compared to the previous year.

The Onesource Specialty Pharma EBIT Growth history

The Onesource Specialty Pharma EBIT Growth history
YEAREBIT GrowthYoY
-86.80 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Onesource Specialty Pharma Stock analysis

What does Onesource Specialty Pharma do? Onesource Specialty Pharma Ltd operates as a specialty pharma pure-play contract development and manufacturing organization (CDMO) within the Life Sciences Tools & Services industry. Based in Bangalore, Karnataka, the India-based company provides vertically integrated biopharma services, focusing on the development and manufacture of complex biologics, biosimilars, and vaccines. Its core offerings include prefilled syringes with or without safety devices, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors. The firm supports the development of complex biologics such as microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and ribonucleic acid (RNA) products. The company generates revenue by catering to a variety of capsule shapes and sizes through its integrated services. These services encompass formulations ranging from traditional softgels to enteric coated capsules, vegan alternatives, chewable formats, vaginal pessaries, liposomal capsules, applicaps, and su. By providing comprehensive biologics solutions, the firm serves clients requiring advanced manufacturing capabilities for diverse pharmaceutical delivery systems and therapeutic modalities. Onesource Specialty Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Onesource Specialty Pharma stock

Year-over-Year EBIT Growth of Onesource Specialty Pharma is -86.80 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Onesource Specialty Pharma since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Onesource Specialty Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Onesource Specialty Pharma

All Key Metrics — Onesource Specialty Pharma